Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis.

Kalakota K, Rakhno E, Pelizzari CA, Jani AB, Liauw SL.

Brachytherapy. 2010 Apr-Jun;9(2):131-6. doi: 10.1016/j.brachy.2009.08.012. Epub 2009 Oct 22.

PMID:
19853533
2.
3.

Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?

Stone NN, Cesaretti JA, Rosenstein B, Stock RG.

Brachytherapy. 2010 Apr-Jun;9(2):114-8. doi: 10.1016/j.brachy.2009.08.002. Epub 2009 Oct 30.

PMID:
19879812
4.

Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.

Corriveau J, Wallner K, Merrick G, True L, Cavanagh W, Sutlief S, Butler W.

Brachytherapy. 2003;2(2):108-13.

PMID:
15062149
6.

Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis.

Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN.

Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):335-41.

PMID:
11380219
7.

Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.

Zelefsky MJ, Nedelka MA, Arican ZL, Yamada Y, Cohen GN, Shippy AM, Park JJ, Zaider M.

Brachytherapy. 2008 Jan-Mar;7(1):1-6. doi: 10.1016/j.brachy.2007.12.002.

PMID:
18299108
8.

The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials.

Ghaly M, Wallner K, Merrick G, True L, Sutlief S, Cavanagh W, Butler W.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1288-93.

PMID:
12654439
9.

Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.

Koontz BF, Chino J, Lee WR, Hahn CA, Buckley N, Huang S, Kim J, Reagan R, Joyner R, Anscher MS.

Brachytherapy. 2009 Apr-Jun;8(2):191-6. doi: 10.1016/j.brachy.2009.01.002.

PMID:
19433320
10.
11.

Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.

Vargas C, Yan D, Kestin LL, Krauss D, Lockman DM, Brabbins DS, Martinez AA.

Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):141-9.

PMID:
16111582
12.

Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.

Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):235-41. doi: 10.1016/j.ijrobp.2010.09.058. Epub 2010 Dec 14.

PMID:
21163587
13.

Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.

Fang FM, Wang YM, Wang CJ, Huang HY, Chiang PH.

Jpn J Clin Oncol. 2008 Jul;38(7):474-9. doi: 10.1093/jjco/hyn056. Epub 2008 Jul 11.

14.

Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer.

Skala M, Rosewall T, Dawson L, Divanbeigi L, Lockwood G, Thomas C, Crook J, Chung P, Warde P, Catton C.

Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):690-8. Epub 2007 Mar 26.

PMID:
17379434
15.

External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity.

Devisetty K, Zorn KC, Katz MH, Jani AB, Liauw SL.

Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1060-5. doi: 10.1016/j.ijrobp.2009.06.078. Epub 2010 Jan 4.

PMID:
20045267
16.

Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.

Ohashi T, Yorozu A, Toya K, Saito S, Momma T, Nagata H, Kosugi M.

Jpn J Clin Oncol. 2007 Feb;37(2):121-6. Epub 2007 Jan 25.

17.

Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.

Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. Review.

PMID:
16029785
18.

Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients.

Shiraishi Y, Yorozu A, Ohashi T, Toya K, Seki S, Yoshida K, Kaneda T, Saito S, Nishiyama T, Hanada T, Shigematsu N.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e127-33. doi: 10.1016/j.ijrobp.2011.01.012. Epub 2011 Mar 11.

PMID:
21398047
19.

Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.

Ishiyama H, Kitano M, Satoh T, Kotani S, Uemae M, Matsumoto K, Okusa H, Tabata K, Baba S, Hayakawa K.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):23-8. doi: 10.1016/j.ijrobp.2008.11.006. Epub 2009 Feb 23.

PMID:
19243900
20.

The effect of obesity on rectal dosimetry after permanent prostate brachytherapy.

Patil N, Crook J, Saibishkumar EP, Aneja M, Borg J, Pond G, Ma C.

Brachytherapy. 2009 Apr-Jun;8(2):218-22. doi: 10.1016/j.brachy.2008.12.001. Epub 2009 Feb 20.

PMID:
19230790
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk